Targeted Protein Degradation in Cancer: How PROTACs and Molecular Glues Are Transforming Precision Oncology

 

Targeted Protein Degradation in Cancer: How PROTACs and Molecular Glues Are Transforming Precision Oncology

Introduction

Cancer treatment has traditionally relied on a simple pharmacological principle: identify a disease-driving protein and develop a drug capable of blocking its activity. This approach has produced major advances in oncology, particularly with kinase inhibitors, hormone receptor antagonists, and other targeted therapies. However, many cancer-associated proteins remain difficult to inhibit effectively because they lack suitable binding pockets, operate through complex protein interactions, or develop mutations that allow cancer cells to escape treatment.

Targeted protein degradation (TPD) is emerging as a fundamentally different strategy.

Instead of simply inhibiting a cancer-driving protein, targeted protein degradation aims to remove the protein itself from the cell. The approach can redirect the cell's natural protein-disposal machinery toward a selected disease-associated protein, potentially producing deeper and more sustained biological effects.

Two of the most important technologies in this field are proteolysis-targeting chimeras (PROTACs) and molecular glue degraders. Both can exploit the ubiquitin-proteasome system to eliminate selected proteins, but they achieve this through different molecular mechanisms.

Recent research published in 2026 continues to expand the field, including work on new degradation mechanisms, tumor-selective delivery, molecular glue discovery, AI-assisted degrader design, and clinical translation.

For precision oncology, the significance is considerable: targeted protein degradation could expand the range of proteins that can be therapeutically manipulated, address certain mechanisms of drug resistance, and create new opportunities for personalized cancer treatment.

 

What Is Targeted Protein Degradation in Cancer?

Targeted protein degradation is a therapeutic strategy designed to selectively eliminate specific proteins inside or around cancer cells.

Traditional inhibitors generally work through occupancy-driven pharmacology. A drug binds to a target protein and blocks its function for as long as sufficient drug remains bound.

TPD takes a different approach.

A degrader brings a target protein into proximity with components of the cell's protein-degradation machinery. This can result in the target being tagged with ubiquitin, followed by recognition and destruction by the proteasome.

The important distinction is that the therapeutic objective is not simply:

"Block the protein."

It is:

"Remove the protein."

This distinction has generated considerable interest in oncology because some proteins may be difficult to inhibit but potentially susceptible to degradation. Recent reviews describe TPD as an expanding therapeutic platform that includes PROTACs, molecular glues, and newer degradation approaches involving lysosomes and autophagy.

 

Why Protein Degradation Is Different From Protein Inhibition

Traditional targeted therapies can be highly effective, but they also have limitations.

A conventional inhibitor may:

• Require continuous target occupancy
• Lose effectiveness when the target mutates
• Be unable to bind certain protein surfaces
• Fail to eliminate non-enzymatic or scaffolding functions
• Be affected by high target-protein expression
• Require sufficiently high systemic exposure

Protein degradation introduces a different pharmacological concept.

A degrader can potentially trigger the removal of multiple target-protein molecules through a catalytic or event-driven mechanism.

This means the biological effect does not necessarily depend on maintaining a one-to-one drug-to-protein relationship.

Researchers are therefore investigating whether degradation can provide stronger target suppression, longer-lasting effects, or access to proteins that conventional inhibitors cannot adequately control.

 

How the Ubiquitin-Proteasome System Works

The ubiquitin-proteasome system (UPS) is one of the major protein-quality-control systems in human cells.

Proteins that need to be eliminated can be tagged with a small protein called ubiquitin.

A simplified process involves:

1. Recognition of a target protein
2. Recruitment of an E3 ubiquitin ligase
3. Transfer of ubiquitin onto the target
4. Formation of a ubiquitin signal
5. Recognition by the proteasome
6. Proteolytic degradation of the target protein

Cancer cells frequently depend on specific proteins to maintain proliferation, survival, DNA repair, metabolism, and resistance to therapy.

TPD researchers attempt to redirect this natural cellular machinery toward those proteins.

The result is a pharmacological strategy that converts the cell's own degradation system into a therapeutic tool.

 

How PROTACs Work

PROTACs, or proteolysis-targeting chimeras, are among the best-known targeted protein degraders.

A typical PROTAC contains three functional components:

1. Target Protein Ligand

This component recognizes the protein of interest (POI).

The protein could be an oncogenic driver, transcriptional regulator, hormone receptor, or another disease-associated protein.

2. Linker

The linker connects the target-binding component with the E3 ligase-recruiting component.

Linker length, flexibility, chemistry, and molecular geometry can strongly influence degrader performance.

3. E3 Ligase Ligand

This component recruits an E3 ubiquitin ligase.

The resulting interaction brings the target protein and E3 ligase into proximity, facilitating ubiquitination and subsequent degradation.

In simplified form:

PROTAC → Target Protein + E3 Ligase → Ubiquitination → Proteasome → Protein Degradation

This mechanism distinguishes PROTACs from many conventional inhibitors.

Recent cancer research continues to explore how target selection, E3 ligase choice, linker design, and molecular architecture influence therapeutic performance.

 

Understanding Molecular Glue Degraders

Molecular glues are another important class of targeted protein degraders.

Unlike conventional PROTACs, which are generally designed as bifunctional molecules containing separate target- and E3-binding components, molecular glues can promote or stabilize an interaction between proteins using a much smaller molecular architecture.

The compound effectively encourages two proteins to interact in a way that results in ubiquitination and degradation of the selected protein.

This creates an important opportunity for drug discovery.

Molecular glues may be capable of engaging proteins or protein surfaces that are difficult to address using conventional small-molecule inhibitors.

Research published in 2026 has highlighted new strategies for discovering molecular glues and expanding the range of E3 ligases and target proteins available for degradation.

 

PROTACs vs Molecular Glues

Although both approaches belong to targeted protein degradation, they are not identical.

Feature	PROTACs	Molecular Glues
Basic architecture	Usually bifunctional	Usually smaller and monovalent
Target recruitment	Designed target-binding ligand	Often induced/stabilized interaction
E3 ligase recruitment	Deliberately engineered	Often discovered through screening
Molecular size	Often relatively large	Generally smaller
Design strategy	More modular	Often more discovery-driven
Drug-like properties	Can be challenging	Potentially favorable in some cases
Discovery	Structure-guided and rational approaches	Screening and chemoproteomic approaches
Therapeutic potential	Broad and rapidly expanding	Increasingly important for difficult targets

The two approaches should not be viewed as competing technologies. Instead, they represent complementary strategies for expanding the protein-degradation landscape.

 

Targeting Previously "Undruggable" Cancer Proteins

One of the biggest attractions of targeted protein degradation is its potential to address proteins traditionally described as "undruggable."

Some proteins lack well-defined pockets suitable for conventional inhibitor binding.

Others function primarily through:

• Protein-protein interactions
• Transcriptional regulation
• Structural scaffolding
• Complex formation
• Non-enzymatic signaling

A degrader does not necessarily need to inhibit the target's active site.

Instead, it needs to create or stabilize an interaction that leads to the target's destruction.

This has encouraged researchers to explore degradation strategies against difficult cancer targets, including transcription factors and other regulatory proteins.

The concept could substantially expand the therapeutic target space in oncology.

 

Targeted Protein Degradation and Precision Oncology

Precision oncology aims to match cancer treatment with the molecular characteristics of an individual's tumor.

TPD could fit naturally into this framework.

A future precision-oncology workflow might involve:

Tumor profiling → Molecular alteration identification → Target selection → Degrader selection → Patient-specific treatment

For example, if a patient's tumor depends strongly on a particular oncogenic protein, researchers may investigate whether that protein can be selectively degraded.

This could complement:

• Genomic profiling
• Transcriptomic analysis
• Proteomics
• Functional screening
• Biomarker analysis
• Liquid biopsy
• Multi-omics approaches

Targeted protein degradation therefore has the potential to become another layer of personalized cancer treatment.

 

TPD and Cancer Drug Resistance

Cancer treatment resistance remains one of the biggest challenges in oncology.

Tumors can develop resistance through:

• Target mutations
• Target amplification
• Alternative signaling pathways
• Increased drug efflux
• Pathway reactivation
• Phenotypic adaptation
• Tumor heterogeneity

Because degradation removes the target protein rather than simply blocking one functional site, researchers are investigating whether TPD can overcome certain forms of resistance.

However, degradation is not automatically resistant to resistance.

Cancer cells may still adapt through:

• Mutations affecting degrader binding
• Changes in E3 ligase expression
• Altered ubiquitin-system activity
• Proteasome alterations
• Reduced intracellular drug concentration
• Activation of compensatory pathways

Therefore, understanding resistance mechanisms will remain an important area of research.

 

Targeted Protein Degradation in Hormone-Driven Cancers

Hormone receptors have become an important area of protein-degradation research.

In hormone-driven cancers, proteins such as estrogen receptor and androgen receptor can act as major drivers of tumor growth.

Conventional endocrine therapies generally interfere with receptor signaling.

Protein degradation offers another possibility: eliminate the receptor itself.

The development of estrogen receptor-directed degraders illustrates the clinical relevance of this concept. Research is also exploring innovative molecular architectures that combine molecular glue principles with PROTAC design to promote degradation of challenging targets such as estrogen receptor alpha.

This area could become particularly important for tumors that develop resistance to conventional hormone therapies.

 

TPD in Hematological Malignancies

Targeted degradation is also being explored in blood cancers.

Hematological malignancies often depend on abnormal transcriptional programs, signaling proteins, and regulatory factors.

Because many of these proteins can be difficult to inhibit directly, researchers are investigating whether targeted degradation can provide an alternative method of disrupting malignant cellular programs.

Potential applications include:

• Leukemias
• Lymphomas
• Multiple myeloma
• Other hematologic cancers

The ability to eliminate selected regulatory proteins could provide new approaches to cancers that become resistant to existing targeted therapies.

 

Targeted Protein Degradation and Cancer Immunotherapy

Another major area of investigation is the relationship between TPD and cancer immunotherapy.

The tumor immune environment is regulated by numerous proteins involved in:

• Immune-cell activation
• Immune suppression
• Antigen presentation
• Cytokine signaling
• T-cell exhaustion
• Tumor immune escape

Researchers are investigating whether targeted degradation can modify these pathways and potentially improve immune-mediated tumor destruction.

Recent reviews specifically examine how targeted protein degradation could be combined with cancer immunotherapy and how delivery strategies may influence this emerging field.

 

Can Protein Degradation Target Immune Checkpoints?

Immune checkpoints are traditionally targeted using antibodies.

However, targeted protein degradation creates the possibility of manipulating checkpoint-related proteins through intracellular or alternative degradation mechanisms.

Potential objectives include:

• Reducing immunosuppressive signaling
• Enhancing T-cell activity
• Modifying tumor immune evasion
• Improving responses to immune checkpoint inhibitors
• Developing combination therapies

The field remains under active investigation, but it represents an important intersection between chemical biology and cancer immunology.

 

TPD and the Tumor Microenvironment

The tumor microenvironment contains:

• Cancer cells
• T cells
• Macrophages
• Fibroblasts
• Endothelial cells
• Extracellular matrix
• Cytokines
• Growth factors

These components interact continuously and influence tumor progression and therapeutic response.

Targeted protein degradation could eventually be designed to act selectively within tumor-associated cellular environments.

Researchers are therefore exploring strategies that exploit:

• Tumor-specific receptors
• Tumor-associated biomarkers
• Hypoxic conditions
• Tumor-associated enzymes
• Local pH
• Tumor-specific signaling environments

The objective is to increase activity at the tumor site while reducing systemic exposure.

 

Next-Generation Protein Degraders

The field is moving beyond traditional PROTAC architectures.

Researchers are investigating multiple degradation platforms, including:

• PROTACs
• Molecular glues
• LYTACs
• AUTACs
• ATTECs
• AbTACs
• GlueTACs
• Stimuli-activated degraders
• Nanoparticle-based degraders

These technologies differ in the cellular compartment and degradation machinery they exploit.

Recent reviews describe targeted proteolysis as an expanding technological ecosystem rather than a single drug-development strategy.

 

Lysosome-Targeting Approaches

The proteasome is not the only cellular degradation system that researchers can exploit.

Some emerging platforms aim to redirect proteins toward the lysosome, an organelle involved in cellular degradation.

This can potentially broaden the range of targets that can be eliminated, including proteins located in cellular compartments that are less accessible to conventional PROTAC approaches.

Lysosome-targeting strategies may therefore complement proteasome-dependent degradation.

 

Antibody-Based Protein Degradation

Antibody-based targeted degradation is another emerging direction.

Antibodies can provide highly selective recognition of extracellular or cell-surface targets.

Researchers are exploring whether antibody-based systems can connect disease-associated proteins with cellular degradation mechanisms.

This could potentially expand protein degradation beyond intracellular proteins.

Such approaches may be particularly relevant for membrane proteins and extracellular targets.

 

AI-Assisted Targeted Protein Degradation

Artificial intelligence and machine learning are becoming increasingly relevant to degrader development.

Designing an effective degrader requires understanding:

• Protein structure
• Ligand binding
• Ternary complex formation
• E3 ligase recruitment
• Linker geometry
• Molecular properties
• Cellular permeability
• Degradation efficiency

Machine learning can potentially assist with:

• Virtual screening
• Molecular-property prediction
• Ligand discovery
• Ternary-complex modeling
• Degrader optimization
• Generative molecular design

A 2026 technical review highlighted machine-learning applications in PROTAC and molecular-glue design, including predictive modeling, virtual screening, and generative approaches.

This creates an increasingly important connection between AI, structural biology, chemical biology, and precision oncology.

 

Drug Delivery: One of the Biggest Challenges

One of the major barriers to TPD development is delivery.

Many PROTAC molecules are relatively large and may have physicochemical properties that make conventional drug delivery difficult.

Challenges can include:

• Limited oral bioavailability
• Poor solubility
• Limited membrane permeability
• Rapid metabolism
• Short or unsuitable exposure
• Poor tumor penetration
• Off-target distribution

Recent 2026 research has emphasized targeted delivery and nanomedicine as potential solutions to these challenges.

Potential approaches include:

• Nanoparticles
• Antibody conjugates
• Peptide-based delivery
• Aptamer-based delivery
• Tumor-targeted ligands
• Stimuli-responsive systems

 

Tumor-Selective Protein Degradation

An important goal is to make degradation occur preferentially in cancer cells.

Researchers are exploring strategies that exploit characteristics of tumors that differ from healthy tissues.

These include:

• Tumor-associated surface receptors
• Unique enzymatic environments
• Hypoxia
• Abnormal pH
• Tumor-specific molecular markers
• Cancer-specific signaling pathways

Some approaches use conditionally activated degraders, which remain relatively inactive until they encounter specific tumor-associated conditions.

This could potentially improve the therapeutic window.

Recent work specifically discusses tumor-selective PROTAC strategies based on tumor biomarkers and the tumor microenvironment.

 

Selectivity and Off-Target Effects

Precision is critical for protein degraders.

A successful therapeutic must ideally degrade the intended protein without producing unacceptable degradation of unintended proteins.

Potential sources of unwanted activity include:

• Off-target ligand binding
• Unexpected protein interactions
• E3 ligase-related effects
• Tissue-specific differences
• Excessive degradation
• Altered cellular proteostasis

Improving selectivity remains one of the major scientific priorities in the field.

Researchers are therefore working to improve:

• Target-binding specificity
• E3 ligase selection
• Linker architecture
• Ternary complex formation
• Tumor-specific activation
• Delivery systems

 

Clinical Translation of PROTACs

The transition from laboratory discovery to clinical medicine is one of the most important stages for TPD.

The field has moved from proof-of-concept studies toward clinical development, with increasing attention on pharmacokinetics, safety, target engagement, degradation biomarkers, and patient selection.

Importantly, 2026 brought a major regulatory milestone for the field: a review published in Advanced Drug Delivery Reviews notes the May 2026 U.S. FDA approval of vepdegestrant as a landmark for heterobifunctional protein-degradation therapeutics.

This development reinforces the transition of targeted protein degradation from an experimental concept toward a clinically validated therapeutic modality.

 

Biomarkers for Targeted Protein Degradation

As TPD moves toward personalized medicine, biomarkers will become increasingly important.

Potential biomarkers could help determine:

• Whether the target protein is present
• Whether the target is essential for tumor survival
• Whether an appropriate E3 ligase is available
• Whether degradation occurs after treatment
• Whether the tumor is developing resistance
• Whether combination therapy is appropriate

Possible biomarker approaches include:

Genomic Biomarkers

Identify mutations or amplifications that create target dependencies.

Transcriptomic Biomarkers

Measure gene-expression patterns associated with treatment sensitivity.

Proteomic Biomarkers

Measure the abundance of target proteins and pathway components.

Pharmacodynamic Biomarkers

Determine whether the intended protein has actually been degraded.

Functional Biomarkers

Assess whether degradation produces the expected biological effect.

This could make TPD particularly compatible with multi-omics precision oncology.

 

Combining TPD With Other Cancer Treatments

Protein degraders do not necessarily have to be used alone.

Combination strategies are being investigated with:

• Kinase inhibitors
• Hormonal therapies
• Chemotherapy
• DNA-damage response inhibitors
• PARP inhibitors
• Immune checkpoint inhibitors
• Cancer vaccines
• Cellular immunotherapies

Combination therapy could be particularly valuable when tumors rely on multiple survival pathways.

For example, degradation of a resistance-associated protein could potentially restore sensitivity to another therapy.

Recent research also highlights the possibility of combining TPD with immunotherapy, nanomedicine, and other targeted platforms.

 

Protein Degradation and Cancer Drug Discovery

TPD could change how pharmaceutical researchers approach drug discovery.

Traditional drug discovery often asks:

"Can we find a molecule that inhibits this protein?"

TPD introduces another question:

"Can we find a molecule that causes the cell to eliminate this protein?"

This change expands the design space.

Researchers can investigate:

• New target proteins
• New E3 ligases
• New ligand classes
• New molecular glue mechanisms
• New degradation pathways
• New delivery technologies

The discovery of additional E3 ligases is particularly important because current degrader development relies on a relatively limited portion of the enormous biological diversity of ubiquitin ligases.

Expanding the E3 ligase toolbox could therefore enable degradation of new classes of cancer-associated proteins.

 

Challenges in Developing Molecular Glues

Despite their promise, molecular glues also present major challenges.

Unlike conventional PROTACs, whose architecture can be designed more explicitly, molecular glue discovery can be less predictable.

Researchers must understand:

• Which proteins will interact
• Which E3 ligase will be recruited
• How the molecular glue changes the interaction surface
• Whether degradation will be selective
• How the ternary complex behaves
• Whether the compound has suitable pharmacological properties

Advanced screening, chemoproteomics, structural biology, and computational methods are increasingly important in this area.

 

Resistance to Targeted Protein Degradation

As TPD therapies progress clinically, resistance will remain an important concern.

Cancer cells could potentially resist degraders by:

• Mutating the target-binding site
• Altering E3 ligase expression
• Losing the relevant E3 ligase
• Altering ubiquitin-pathway components
• Changing proteasome activity
• Increasing drug efflux
• Activating alternative survival pathways

Understanding these mechanisms early could help researchers design next-generation degraders and rational combination treatments.

 

The Future of Targeted Protein Degradation in Oncology

The future of TPD will likely involve several technologies developing simultaneously.

More Selective Degraders

Researchers will aim to increase cancer-cell specificity and reduce unwanted systemic effects.

Better Delivery

Nanoparticles and tumor-targeting technologies may improve exposure at the tumor site.

New E3 Ligases

Expanding the E3 ligase repertoire could unlock additional targets.

AI-Driven Design

Machine learning could accelerate degrader discovery and optimization.

Combination Therapies

TPD may increasingly be integrated with immunotherapy, targeted therapy, and other precision treatments.

Multi-Omics Patient Selection

Genomics, transcriptomics, proteomics, and functional testing may help identify patients most likely to benefit.

New Degradation Mechanisms

Proteasome-independent technologies may expand the range of proteins and cellular compartments that can be targeted.

 

Why Targeted Protein Degradation Matters for Precision Oncology

The most important promise of targeted protein degradation is not simply that it represents a new class of drugs.

Its deeper significance is that it changes the therapeutic relationship between a drug and its target.

Instead of continuously blocking a protein, the therapeutic goal can be to remove it.

Instead of focusing exclusively on proteins with convenient inhibitor-binding pockets, researchers can investigate proteins that may previously have been considered difficult to drug.

Instead of relying only on traditional pharmacology, TPD combines:

• Chemical biology
• Molecular pharmacology
• Structural biology
• Proteomics
• Cancer genomics
• Drug delivery
• Artificial intelligence
• Precision medicine

This convergence could make targeted protein degradation one of the important technology platforms shaping the next generation of cancer therapeutics.

 

Conclusion

Targeted protein degradation in cancer represents a major evolution in precision medicine.

PROTACs and molecular glues are demonstrating how the cell's natural protein-degradation machinery can be redirected toward disease-associated proteins. At the same time, emerging technologies are expanding the field toward lysosomal degradation, antibody-based systems, tumor-selective delivery, stimuli-responsive degraders, and AI-assisted molecular design.

The scientific challenges remain substantial. Drug delivery, selectivity, pharmacokinetics, toxicity, resistance, biomarker development, and patient selection must all be addressed before the full potential of TPD can be realized.

Nevertheless, the rapid progress of the field—including important clinical and regulatory developments in 2026—suggests that protein degradation is moving beyond an experimental concept and toward a meaningful component of modern oncology drug development.

For researchers, clinicians, pharmaceutical scientists, and biotechnology innovators, targeted protein degradation offers an exciting opportunity to rethink how cancer-driving proteins can be targeted, eliminated, and ultimately translated into more precise treatment strategies.

The future of precision oncology may not only depend on finding better ways to inhibit cancer proteins—it may depend on finding better ways to make cancer cells eliminate them.

Explore the latest developments in oncology, precision medicine, cancer therapeutics, and emerging technologies at the International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027), taking place March 25–27, 2027, in Osaka, Japan.

The summit brings together researchers, clinicians, healthcare professionals, academic experts, pharmaceutical scientists, and industry leaders to discuss emerging innovations shaping the future of cancer diagnosis, treatment, and care.

FAQs

1. What is targeted protein degradation in cancer?

Targeted protein degradation is a therapeutic approach that selectively removes disease-driving proteins from cancer cells using cellular degradation machinery.

2. What are PROTACs in cancer treatment?

PROTACs are molecules that bring a target protein and an E3 ubiquitin ligase together, triggering ubiquitination and subsequent protein degradation.

3. What are molecular glues in cancer?

Molecular glues are small molecules that promote or stabilize interactions between proteins, often leading to selective degradation of disease-associated proteins.

4. How are PROTACs different from traditional cancer drugs?

Traditional inhibitors usually block a protein's activity, whereas PROTACs aim to eliminate the target protein itself through targeted degradation.

5. Can targeted protein degradation address undruggable cancer targets?

Potentially. TPD can target some proteins that are difficult to inhibit with conventional drugs, including certain regulatory and scaffolding proteins.

6. Can protein degradation help overcome cancer drug resistance?

TPD may help address some resistance mechanisms, although cancer cells can also develop resistance to degraders through target mutations, altered E3 ligases, or other cellular adaptations.

7. What are the major challenges of targeted protein degradation?

Major challenges include drug delivery, bioavailability, tumor selectivity, off-target effects, pharmacokinetics, resistance, and identifying suitable biomarkers.

8. Can AI improve PROTAC and molecular glue development?

Yes. Machine learning is being investigated for virtual screening, predictive modeling, molecular design, and optimization of protein degraders.

9. Is targeted protein degradation being studied clinically?

Yes. TPD has progressed from laboratory research into clinical development, with ongoing efforts to improve therapeutic delivery, selectivity, and clinical effectiveness.

10. What is the future of targeted protein degradation in oncology?

Future research is expected to focus on tumor-selective degraders, new E3 ligases, improved delivery systems, molecular glues, AI-assisted design, and combination therapies